Cholesterol is carried in the blood attached to proteins called lipoproteins. Low-density lipoprotein cholesterol (LDL-C) is considered the “bad” cholesterol because it contributes to plaque, a thick, hard deposit that can clog arteries and make them less flexible.
Shares of Esperion Therapeutics, Inc. (Nasdaq:ESPR) soared to touch a new 52-week high in intraday trading Monday after the company said that the U.S. Food and Drug Administration (FDA) recently confirmed that its LDL-C lowering program is adequate to support approval of an LDL-C lowering indication for bempedoic acid.
Analysts at Credit Suisse upgraded the company's stock from an Underperform to a Neutral rating, following the announcement.
With a targeted mechanism of action, Esperion's bempedoic acid is a first-in-class, orally available, once-daily ACL inhibitor that has been shown to reduce cholesterol biosynthesis and lower elevated levels of LDL-C by up-regulating the LDL receptor, but may potentially reduce the occurrence of muscle-related side effects.
ESPR stock is trading at $38.99, up $15.32 (or +64.70%) and 17.52M of its shares changed hands so far.
Esperion Therapeutics is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer